Elicio Therapeutics Shares Drop 35% After Public Offering Prices

By Chris Wack Elicio Therapeutics shares fell after an underwritten public offering with proceeds of up to $11.5 million priced at $5 a unit. The clinical-stage biotechnology company's stock was dow

WSJJun 28 13:49 ET

Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?

Thursday, Elicio Therapeutics Inc (NASDAQ:ELTX) released new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-

BenzingaJun 28 11:41 ET

Elicio Therapeutics to Place With Certain Investors in Lieu of Common Stock Up to 1.8M Shares at $5 a Share >ELTX

Elicio Therapeutics to Place With Certain Investors in Lieu of Common Stock Up to 1.8M Shares at $5 a Share >ELTX

Dow JonesJun 28 09:06 ET

Elicio Therapeutics to Use Net Proceeds for the Advancement of Development Pipeline >ELTX

Elicio Therapeutics to Use Net Proceeds for the Advancement of Development Pipeline >ELTX

Dow JonesJun 28 09:03 ET

Express News | Elicio Therapeutics Prices $11.5M Underwritten Public Offering Of 500,000 Shares And Accompanying Common Warrants At $5.00/Share And Accompanying Common Warrant

BenzingaJun 28 09:01 ET

Express News | Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

ReutersJun 28 09:00 ET